Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.



Jonathan Rohll's Articles

Isansys Lifecare partners with myHealth Sentinel

Oxford, UK: Isansys Lifecare, a global health technology company, is delighted to announce its partnership with myHealth Sentinel (mHS) to offer its wireless, wearable, continuous patient data capture and analysis platform in Singapore.

Wessex Academic Health Science Network and Wessex Clinical Research Network launch their Technology Support Programme (Round 1)

Wessex Clinical Research Network (CRN) and Wessex Academic Health Science Network (AHSN) have teamed up to support commercial innovators gather crucial evidence on their products.  Their new Technology Support Programme (TSP) will help companies to access the NHS’s research infrastructure to obtain high quality evidence on the economic and health gains their products can bring.

Isansys travels with NASA to Antarctica

NASA to evaluate the use of Isansys’ physiological monitoring tools to learn how to monitor explorers as they travel into space.  A NASA exploration scientist set off on his mission to Antarctica being monitored by the Patient Status Engine, a physiological data collection platform which provides monitoring of individuals wirelessly and in real-time.

OBN Celebrates Successful Inaugural BioSeed® Conference Supporting Innovative Life Sciences Companies’ Accessing Seed Funding

BioSeed® has been designed to provide a platform for innovative life science companies to present and meet with sector specific early stage investors.

Genomics plc teams up with Biogen to discover new drug targets for multiple sclerosis

Oxford, UK:  Genomics plc today announced that it has entered into a collaborative deal with Biogen, Inc., the U.S.-based biotech, to work on multiple sclerosis (MS). Biogen is an international leader in drug therapies for MS, with the broadest MS portfolio in the industry.

OBN Announce Award Winners

Press Release OBN Awards 2017 – Winners Recognised at Industry Leading Event   Abingdon, UK, 6 October 2017: – OBN (UK) Ltd, the membership organisation that supports the life sciences industry, are delighted to announce the winners of the prestigious OBN Awards 2017 that were presented last night in front of a sold-out audience of over 250 life science industry leaders at the Town Hall in Oxford.    The Awards, which are in their 9th year, celebrate the best of UK life sciences – from outstanding scientific innovation within biotech, medtech, digital, synthetic biology, to the companies that support the industry and the fundraisers that make it happen.   John Harris, CEO of OBN, said: “We received an outstanding number of entries this year; up a staggering 120% on last year, so competition was really tough.  All of our winners and nominees this year are truly innovative and set a great example to the rest of the industry.   We ...

PsiOxus Therapeutics Expands operations in both Oxford, UK and Philadelphia, USA

Oxford, UK - PsiOxus Therapeutics, Ltd. (PsiOxus), the cancer therapeutics company, today announced expansion of operations into a 21,000 sq ft state-of-the-art facility on the Abingdon Science Park in Oxfordshire, UK. Additionally, PsiOxus announced the opening of a new US facility in Plymouth Meeting near Philadelphia, Pennsylvania. This dual expansion will allow PsiOxus to accelerate the research and development of novel immune-oncology products in both the UK and the US.

OBN Appoints New Non-Executive Director to Enhance Board Expertise

Abingdon, UK: OBN the membership organisation supporting the UK’s innovative life sciences companies, announces today the appointment of Bill Fleming to its Board of Directors, effective immediately

Adaptimmune Therapeutics plc Announces Closing of $42 Million Registered Direct Offering

Philadelphia, USA and Oxford, UK:  Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced registered direct offering of its American Depositary Shares (“ADSs”) following its entry into a definitive agreement with Matrix Capital Management Company, LP (“Matrix”) to purchase an aggregate of approximately US$42,000,000 of its ADSs. Adaptimmune sold 7,000,000 ADSs at a price of $6.00 per ADS.

MGB Biopharma Closes $1 million Financing Round to Finance Manufacturing of MGB-BP-3 for Phase II Study in Clostridium difficile-Associated Disease (CDAD)

Glasgow, Scotland:  MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance, announces today that it has raised $1.15 million in a financing round with existing investors.

Pages: Previous12NextReturn Top

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.

OBN Noticeboard

This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc.  Just drop an email to us, team@obn.org.uk, and we will post.